Ultragenyx Pharmaceutical Inc. (RARE)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 09:55AM EDT. Market open.
Currency in USD
Valuation measures4
| Market cap (intra-day) | 3.61B |
| Enterprise value | 3.08B |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 7.43 |
| Price/book (mrq) | 13.11 |
| Enterprise value/revenue | 7.08 |
| Enterprise value/EBITDA | -5.96 |
Trading information
Stock price history
| Beta (5Y monthly) | 0.66 |
| 52-week change 3 | 0.41% |
| S&P500 52-week change 3 | 21.08% |
| 52-week high 3 | 54.98 |
| 52-week low 3 | 31.52 |
| 50-day moving average 3 | 47.82 |
| 200-day moving average 3 | 42.12 |
Share statistics
| Avg vol (3-month) 3 | 700.53k |
| Avg vol (10-day) 3 | 832.06k |
| Shares outstanding 5 | 82.34M |
| Implied shares outstanding 6 | 82.34M |
| Float 8 | 72.17M |
| % held by insiders 1 | 4.11% |
| % held by institutions 1 | 101.11% |
| Shares short (15 Apr 2024) 4 | 4.38M |
| Short ratio (15 Apr 2024) 4 | 6.09 |
| Short % of float (15 Apr 2024) 4 | 5.54% |
| Short % of shares outstanding (15 Apr 2024) 4 | 5.32% |
| Shares short (prior month 15 Mar 2024) 4 | 3.78M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Dec 2023 |
Profitability
| Profit margin | -139.70% |
| Operating margin (ttm) | -95.81% |
Management effectiveness
| Return on assets (ttm) | -23.43% |
| Return on equity (ttm) | -193.23% |
Income statement
| Revenue (ttm) | 434.25M |
| Revenue per share (ttm) | 5.91 |
| Quarterly revenue growth (yoy) | 23.30% |
| Gross profit (ttm) | N/A |
| EBITDA | -543.2M |
| Net income avi to common (ttm) | -606.64M |
| Diluted EPS (ttm) | -8.25 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 577.21M |
| Total cash per share (mrq) | 7.01 |
| Total debt (mrq) | 934.74M |
| Total debt/equity (mrq) | 339.39% |
| Current ratio (mrq) | 2.61 |
| Book value per share (mrq) | 3.35 |
Cash flow statement
| Operating cash flow (ttm) | -474.81M |
| Levered free cash flow (ttm) | -312.22M |
© 2024 Yahoo. All rights reserved.